KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) EBITDA Margin (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed EBITDA Margin for 11 consecutive years, with 856.95% as the latest value for Q1 2025.

  • Quarterly EBITDA Margin changed N/A to 856.95% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 359.88% through Dec 2025, changed N/A year-over-year, with the annual reading at 689.79% for FY2025, N/A changed from the prior year.
  • EBITDA Margin for Q1 2025 was 856.95% at Xenon Pharmaceuticals, up from 29632.58% in the prior quarter.
  • The five-year high for EBITDA Margin was 198.14% in Q1 2022, with the low at 29632.58% in Q3 2022.
  • Average EBITDA Margin over 3 years is 4861.85%, with a median of 760.8% recorded in 2025.
  • Peak annual rise in EBITDA Margin hit 17035bps in 2022, while the deepest fall reached -2928595bps in 2022.
  • Over 3 years, EBITDA Margin stood at 664.65% in 2021, then plummeted by -4358bps to 29632.58% in 2022, then skyrocketed by 97bps to 856.95% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 856.95%, 29632.58%, and 5813.06% for Q1 2025, Q3 2022, and Q2 2022 respectively.